Reviewing Data on Lenvatinib plus Pembrolizumab Combination Treatment for Advanced Renal Cell Carcinoma

home / between-the-lines / reviewing-data-on-lenvatinib-plus-pembrolizumab-combination-treatment-for-advanced-renal-cell-ca

A panel of oncologists reviews a publication by Motzer et al. (2021) on data from the CLEAR trial studying lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma treatment and discuss the clinical implications of the results.